Concise Review: Hitting the Right Spot with Mesenchymal Stromal Cells§

Authors

  • Jakub Tolar,

    Corresponding author
    1. Division of Hematology, Oncology, Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA
    • Blood and Marrow Transplant Program, 420 Delaware St. SE, MMC 366, Minneapolis, Minnesota 55455, USA
    Search for more papers by this author
    • Telephone: 612-625-2912; Fax: 612-624-3913

  • Katarina Le Blanc,

    1. Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden
    Search for more papers by this author
  • Armand Keating,

    1. Cell Therapy Program Princess Margaret Hospital, Toronto, Ontario, Canada
    Search for more papers by this author
  • Bruce R. Blazar

    1. Division of Hematology, Oncology, Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA
    Search for more papers by this author

  • Author contributions: J.T.: conception and design, manuscript writing and editing; K.L.B.: manuscript writing and editing; A.K.: manuscript writing and editing.; B.R.B.: conception and design, manuscript writing and editing. J.T., K.L.B., A.K., and B.R.B. contributed equally to this article.

  • Disclosure of potential conflicts of interest is found at the end of this article.

  • §

    First published online in STEM CELLS EXPRESS July 1, 2010.

Abstract

Mesenchymal stromal cells or mesenchymal stem cells (MSCs) have captured considerable scientific and public interest because of their potential to limit physical and immune injury, to produce bioactive molecules and to regenerate tissues. MSCs are phenotypically heterogeneous and distinct subpopulations within MSC cultures are presumed to contribute to tissue repair and the modulation of allogeneic immune responses. As the first example of efficacy, clinical trials for prevention and treatment of graft-versus-host disease after hematopoietic cell transplantation show that MSCs can effectively treat human disease. The view of the mechanisms whereby MSCs function as immunomodulatory and reparative cells has evolved simultaneously. Initially, donor MSCs were thought to replace damaged cells in injured tissues of the recipient. More recently, however, it has become increasingly clear that even transient MSC engraftment may exert favorable effects through the secretion of cytokines and other paracrine factors, which engage and recruit recipient cells in productive tissue repair. Thus, an important reason to investigate MSCs in mechanistic preclinical models and in clinical trials with well-defined end points and controls is to better understand the therapeutic potential of these multifunctional cells. Here, we review the controversies and recent insights into MSC biology, the regulation of alloresponses by MSCs in preclinical models, as well as clinical experience with MSC infusions (Table 1) and the challenges of manufacturing a ready supply of highly defined transplantable MSCs. STEM CELLS 2010;28:1446–1455

Ancillary